Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design.
Journal: Future oncology (London, England)
Published: May 17, 2019
A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 18, 2014
Development and future of the American Society of Clinical Oncology's Quality Oncology Practice Initiative.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 17, 2014
Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop.
Journal: Journal of oncology practice
Published: November 01, 2013
Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.
Journal: Cancer biology & therapy
Published: June 25, 2013
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 28, 2013
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 06, 2012
Showing 1-7 of 7
Last Updated: 09/26/2026